SCORED Trial (Sotagliflozin) Risk Index Calculator
Event-rate assumptions
Use the SCORED placebo rate or enter a different rate.
About this estimate
SCORED enrolled adults with type 2 diabetes, chronic kidney disease (eGFR 25–60 mL/min/1.73 m²), and cardiovascular risk. The trial’s primary endpoint was changed during the study to the total number of cardiovascular deaths, heart-failure hospitalizations, and urgent heart-failure visits.
The reported primary-endpoint rates were 7.5 events per 100 patient-years with placebo and 5.6 with sotagliflozin; the reported HR was 0.74 (95% CI 0.63–0.88). The trial ended early because of loss of funding, with median follow-up of 16 months.
Calculation method
- Estimated treated event rate = baseline event rate × assumed HR.
- Event-rate difference = baseline event rate − estimated treated event rate.
- Relative reduction implied by HR = (1 − HR) × 100%.
Important limitations
- This is an illustrative rate projection using an aggregate trial HR, not a validated individual prediction tool.
- The SCORED endpoint counted total events, including recurrent events. Event rates should not be relabelled as annual patient-level risks.
- Results depend on the assumption that the chosen HR applies to the population and endpoint represented by the entered baseline rate.
- The calculator does not account for confidence intervals, competing risks, adverse effects, contraindications, or an individual patient’s treatment eligibility.
References
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.